Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Immutep ( (IMMP) ) just unveiled an announcement.
On June 23, 2025, Immutep announced positive results from its Phase I study of IMP761, a first-in-class LAG-3 agonist antibody designed to treat autoimmune diseases. The study demonstrated significant T cell suppression and a favorable safety profile at a 0.9 mg/kg dosage, with plans to test higher doses. These findings underscore the potential of IMP761 to effectively target autoimmune diseases, offering a promising therapeutic approach with fewer side effects.
The most recent analyst rating on (IMMP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.
Immutep’s stock is primarily influenced by its challenging financial performance and poor technical indicators. Financials are weak due to negative margins and cash flow issues, mitigated slightly by a solid balance sheet. Technical analysis shows bearish momentum. The valuation is low due to consistent losses, resulting in an overall low stock score.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the research and development of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), aiming to leverage this expertise to provide innovative treatment options and maximize shareholder value.
Average Trading Volume: 293,308
Technical Sentiment Signal: Sell
Current Market Cap: $222.4M
Find detailed analytics on IMMP stock on TipRanks’ Stock Analysis page.